IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Showing posts with label Pfizer. Show all posts
Showing posts with label Pfizer. Show all posts
Tuesday, 30 September 2025

Medicaid to Receive Most Favored Nation Pricing on Pfizer Drugs

›
The White House has announced that President Trump has made a deal with Pfizer for state Medicaid to receive most favored nation pricing on ...
Friday, 27 October 2017

Another Case of Pharma Weakening the Patent System (and University Technology Transfer)

›
The LA Times recently published an article, "UCLA’s Efforts to Patent a Costly Patent Cancer Drug in India Hurts the Poor, Critics ...
Wednesday, 2 February 2011

Farewell Sandwich

›
In the midst of discussions about the future of IP tax and incentives in the UK comes the news that Pfizer is closing its UK R&D facilit...
Saturday, 31 January 2009

Ruminations on the Pfizer-Wyeth Merger

›
Amidst all the economic doom and gloom coming out of Washington, London and Davos (I think they had to do without Sharon Stone and Angelina ...
›
Home
View web version
Powered by Blogger.